Effect of disease-modifying therapies on subcortical gray matter atrophy in multiple sclerosis

Abstract

Background:

The effects of disease-modifying therapies (DMTs) on region-specific brain atrophy in multiple sclerosis (MS) are unclear.

Objective:

To determine the effects of higher versus lower efficacy DMTs on rates of brain substructure atrophy in MS.

Methods:

A non-randomized, observational cohort of people with MS followed with annual brain magnetic resonance imaging (MRI) was evaluated retrospectively. Whole brain, subcortical gray matter (GM), cortical GM, and cerebral white matter (WM) volume fractions were obtained. DMTs were categorized as higher (DMT-H: natalizumab and rituximab) or lower (DMT-L: interferon-beta and glatiramer acetate) efficacy. Follow-up epochs were analyzed if participants had been on a DMT for ⩾6 months prior to baseline and had at least one follow-up MRI while on DMTs in the same category.

Results:

A total of 86 DMT epochs (DMT-H: n = 32; DMT-L: n = 54) from 78 participants fulfilled the study inclusion criteria. Mean follow-up was 2.4 years. Annualized rates of thalamic (−0.15% vs −0.81%; p = 0.001) and putaminal (−0.27% vs −0.73%; p = 0.001) atrophy were slower during DMT-H compared to DMT-L epochs. These results remained significant in multivariate analyses including demographics, clinical characteristics, and T2 lesion volume.

Conclusion:

DMT-H treatment may be associated with slower rates of subcortical GM atrophy, especially of the thalamus and putamen. Thalamic and putaminal volumes are promising imaging biomarkers in MS.

Keywords

Multiple sclerosis quantitative MRI disease-modifying therapies atrophy thalamus biomarkers

Get full access to this article

View all access options for this article.

References

De Stefano

Airas

Grigoriadis

, et al. Clinical relevance of brain volume measures in multiple sclerosis. CNS Drugs 2014; 28(2): 147–156.

Azevedo

Pelletier

Whole-brain atrophy: Ready for implementation into clinical decision-making in multiple sclerosis?

Curr Opin Neurol 2016; 29(3): 237–242.

Rocca

Battaglini

Benedict

RHB

, et al. Brain MRI atrophy quantification in MS: From methods to clinical application. Neurology 2017; 88(4): 403–413.

Wattjes

Rovira Miller

ÀD

Yousry

, et al. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis–establishing disease prognosis and monitoring patients. Nat Rev Neurol 2015; 11(10): 597–606.

Dalton

Chard

Davies

, et al. Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain 2004; 127(Pt 5): 1101–1107.

Houtchens

Benedict

RHB

Killiany

, et al. Thalamic atrophy and cognition in multiple sclerosis. Neurology 2007; 69(12): 1213–1223.

Roosendaal

Bendfeldt

Vrenken

, et al. Grey matter volume in a large cohort of MS patients: Relation to MRI parameters and disability. Mult Scler 2011; 17(9): 1098–1106.

Vidal-Jordana

Sastre-Garriga

Perez-Miralles

, et al. Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes. Mult Scler 2013; 19(9): 1175–1181.

Fisher

Nakamura

Lee

, et al. Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing−remitting multiple sclerosis: A retrospective analysis. Mult Scler 2016; 22(5): 668–676.

10.

Henry

Shieh

Okuda

, et al. Regional grey matter atrophy in clinically isolated syndromes at presentation. J Neurol Neurosurg Psychiatry 2008; 79(11): 1236–1244.

11.

Azevedo

Overton

Khadka

, et al. Early CNS neurodegeneration in radiologically isolated syndrome. Neurol Neuroimmunol Neuroinflamm 2015; 2(3): e102.

12.

Schoonheim

Popescu

RuedaLopes

, et al. Subcortical atrophy and cognition: Sex effects in multiple sclerosis. Neurology 2012; 79(17): 1754–1761.

13.

Polman

Reingold

Edan

, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria.” Ann Neurol 2005; 58(6): 840–846.

14.

Lublin

Reingold

SC.

Defining the clinical course of multiple sclerosis: Results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46(4): 907–911.

15.

Fogarty

Schmitz

Tubridy

, et al. Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis. Mult Scler Relat Disord 2016; 9: 23–30.

16.

Tustison

Avants

Cook

, et al. N4ITK: Improved N3 bias correction. IEEE Trans Med Imaging 2010; 29(6): 1310–1320.

17.

Roy

Butman

Pham

DL.

Robust skull stripping using multiple MR image contrasts insensitive to pathology. Neuroimage 2017; 146: 132–147.

18.

Roy

Carass

Prince

, et al. Subject specific sparse dictionary learning for atlas based brain MRI segmentation. Mach Learn Med Imaging 2014; 8679: 248–255.

19.

Battaglini

Jenkinson

De Stefano

Evaluating and reducing the impact of white matter lesions on brain volume measurements. Hum Brain Mapp 2012; 33(9): 2062–2071.

20.

Huo

Plassard

Carass

, et al. Consistent cortical reconstruction and multi-atlas brain segmentation. Neuroimage 2016; 138: 197–210.

21.

Wang

Suh

Das

, et al. Multi-atlas segmentation with joint label fusion. IEEE Trans Pattern Anal Mach Intell 2013; 7: 27–623.

22.

Shiee

Bazin

Cuzzocreo

, et al. Reconstruction of the human cerebral cortex robust to white matter lesions: Method and validation. Hum Brain Mapp 2014; 35(7): 3385–3401.

23.

Whitwell

Crum

Watt

, et al. Normalization of cerebral volumes by use of intracranial volume: Implications for longitudinal quantitative MR imaging. AJNR Am J Neuroradiol 2001; 22(8): 1483–1489.

24.

Bender

Lange

Adjusting for multiple testing—When and how?

J Clin Epidemiol 2001; 54: 343–349.

25.

Haider

Simeonidou

Steinberger

, et al. Multiple sclerosis deep grey matter: The relation between demyelination, neurodegeneration, inflammation and iron. J Neurol Neurosurg Psychiatry 2014; 85(12): 1386–1395.

26.

Henry

Shieh

Amirbekian

, et al. Connecting white matter injury and thalamic atrophy in clinically isolated syndromes. J Neurol Sci 2009; 282(1–2): 61–66.

27.

Makowski

Béland

Kostopoulos

, et al. Evaluating accuracy of striatal, pallidal, and thalamic segmentation methods: Comparing automated approaches to manual delineation. Neuroimage 2018; 170: 182–198.

28.

Borges

Shea

Ohayon

, et al. The effect of daclizumab on brain atrophy in relapsing-remitting multiple sclerosis. Mult Scler Relat Disord 2013; 2(2): 133–140.

29.

Eshaghi

Prados

Brownlee

, et al. Deep gray matter volume loss drives disability worsening in multiple sclerosis. Ann Neurol 2018; 83(2): 210–222.

30.

Filippi

Rocca

Pagani

, et al. Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. J Neurol Neurosurg Psychiatry 2014; 85(8): 851–858.

31.

Gaetano

Haring

Radue

, et al. Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosis. Neurology 2018; 90(15): e1324.

32.

Sormani

Bruzzi

Can we measure long-term treatment effects in multiple sclerosis?

Nat Rev Neurol 2015; 11(3): 176–182.

33.

Azevedo

Cen

Khadka

, et al. Thalamic atrophy in multiple sclerosis: A magnetic resonance imaging marker of neurodegeneration throughout disease. Ann Neurol 2018; 83(2): 223–234.

34.

Shinohara

Nair

, et al. Volumetric analysis from a harmonized multisite brain MRI study of a single subject with multiple sclerosis. AJNR Am J Neuroradiol 2017; 38(8): 1501–1509.

35.

Huo

Bao

Parvathaneni

, et al. Improved stability of whole brain surface parcellation with multi-atlas segmentation. Proc SPIE Int Soc Opt Eng 2018; 10574: 1057438.

36.

Azevedo

Cen

Zheng

, et al. The varying contribution of normal aging atrophy to MS brain volume measurements across adulthood. Mult Scler 2017; 23(S3): 53–54.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.15 MB

0.23 MB